1. C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation
   Chenhui Zhao et al, 2018, Oncogene CrossRef
2. VASH2 Promotes Cell Proliferation and Resistance to Doxorubicin in Non-Small Cell Lung Cancer via AKT Signaling
   Xiangbin Tan et al, 2020, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics CrossRef
3. Gene expression profiling of spontaneously occurring canine mammary tumours: Insight into gene networks and pathways linked to cancer pathogenesis
   Shahid Hussain et al, 2018, PLOS ONE CrossRef
4. IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis
   Arcangelo Liso et al, 2022, International Journal of Molecular Sciences CrossRef
5. IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker
   Qiuyan Chen et al, 2016, Oncotarget CrossRef
6. The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b
   Wu Zhou et al, 2017, Science Signaling CrossRef
7. Vasohibin2 promotes adriamycin resistance of breast cancer cells through regulating ABCG2 via AKT signaling pathway
   Deliang Ma et al, 2017, Molecular Medicine Reports CrossRef
8. Domain architecture of vasohibins required for their chaperone‐dependent unconventional extracellular release
   Tetsuya Kadonosono et al, 2017, Protein Science CrossRef
9. The roles of vasohibin and its family members: Beyond angiogenesis modulators
   Hua Du et al, 2017, Cancer Biology & Therapy CrossRef
10. Comprehensive Analysis of IGFBPs as Biomarkers in Gastric Cancer
    Qi Liu et al, 2021, Frontiers in Oncology CrossRef
11. Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor β 1 and hypoxia dependent repression of GATA-binding factor 3
    Min Tu et al, 2017, Cancer Letters CrossRef
12. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
    Min Tu et al, 2017, Molecular Cancer CrossRef
13. Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2
    Min Tu et al, 2016, Cancer Letters CrossRef
14. Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer
    Yang Shao et al, 2016, Oncotarget CrossRef
15. Growth differentiation factor-15 and lactoferrin immuno-expression in breast cancer: relationship with body iron-status and survival outcome
    Zheng Zhang et al, 2021, BioMetals CrossRef
16. Vasohibins: new transglutaminase-like cysteine proteases possessing a non-canonical Cys-His-Ser catalytic triad
    Luis Sanchez-Pulido et al, 2016, Bioinformatics CrossRef
17. Decreased expression of IGFBP6 correlates with poor survival in colorectal cancer patients
    Chunmei Zhao et al, 2020, Pathology - Research and Practice CrossRef
18. Post-translational modifications of tubulin: their role in cancers and the regulation of signaling molecules
    Onsurang Wattanathamsan et al, 2023, Cancer Gene Therapy CrossRef
19. Nuclear vasohibin-2 promotes cell proliferation by inducing G0/G1 to S phase progression
    QIANQIAN GE et al, 2015, Oncology Reports CrossRef
20. Targeting human vasohibin‐2 by a neutralizing monoclonal antibody for anti‐cancer treatment
    Takahiro Koyanagi et al, 2017, Cancer Science CrossRef
21. Recent insights into the actions of IGFBP-6
    Leon A. Bach, 2015, Journal of Cell Communication and Signaling CrossRef